SAB Biotherapeutics (SABS) Competitors $2.55 -0.03 (-1.16%) Closing price 04:00 PM EasternExtended Trading$2.55 0.00 (0.00%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. FBIO, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Its Competitors Fortress Biotech Curis Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Is SABS or FBIO more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Fortress Biotech's net margin of -71.24%. SAB Biotherapeutics' return on equity of -105.14% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets SAB BiotherapeuticsN/A -105.14% -69.24% Fortress Biotech -71.24%-4,712.53%-27.67% Which has stronger valuation and earnings, SABS or FBIO? SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSAB Biotherapeutics$1.32M17.95-$34.10M-$3.70-0.69Fortress Biotech$57.78M1.02-$46M-$2.23-0.89 Do analysts recommend SABS or FBIO? SAB Biotherapeutics presently has a consensus price target of $13.25, indicating a potential upside of 419.61%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 955.28%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SABS or FBIO? In the previous week, SAB Biotherapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score. Company Overall Sentiment SAB Biotherapeutics Neutral Fortress Biotech Neutral Which has more risk and volatility, SABS or FBIO? SAB Biotherapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Do institutionals and insiders have more ownership in SABS or FBIO? 7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 27.8% of SAB Biotherapeutics shares are held by insiders. Comparatively, 27.9% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummarySAB Biotherapeutics and Fortress Biotech tied by winning 7 of the 14 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.69M$2.92B$5.54B$9.01BDividend YieldN/A2.45%5.25%4.03%P/E Ratio-0.6921.1428.0720.17Price / Sales17.95288.58431.98124.59Price / CashN/A41.1936.8257.86Price / Book0.917.868.125.62Net Income-$34.10M-$54.95M$3.16B$248.50M7 Day Performance45.71%6.24%4.40%5.54%1 Month Performance37.10%5.70%4.09%7.52%1 Year Performance-11.15%8.08%34.53%22.06% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics3.0373 of 5 stars$2.55-1.2%$13.25+419.6%-9.5%$23.69M$1.32M-0.69140News CoverageGap DownFBIOFortress Biotech2.1431 of 5 stars$1.86+2.2%$21.00+1,029.0%+10.3%$53.82M$57.67M-0.83170Gap UpCRISCuris2.8662 of 5 stars$2.32+6.9%$17.00+632.8%-72.2%$22.70M$10.91M-0.3760High Trading VolumeBOLTBolt Biotherapeutics2.9726 of 5 stars$5.77+2.9%$50.00+766.6%-58.9%$10.75M$7.69M-0.1790Positive NewsHigh Trading VolumeMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.5231 of 5 stars$279.21+0.8%$307.82+10.2%-4.6%$149.01B$33.42B25.4828,000Positive NewsGILDGilead Sciences4.8315 of 5 stars$110.87+0.2%$110.55-0.3%+64.4%$137.67B$28.75B23.3417,600Positive NewsVRTXVertex Pharmaceuticals4.3552 of 5 stars$445.20+0.9%$511.62+14.9%-3.2%$113.32B$11.02B-113.576,100Positive NewsREGNRegeneron Pharmaceuticals4.9174 of 5 stars$525.00+0.8%$813.57+55.0%-47.9%$56.25B$14.20B13.3715,106Analyst RevisionALNYAlnylam Pharmaceuticals4.1007 of 5 stars$326.09+1.0%$340.00+4.3%+24.5%$42.09B$2.25B-156.022,230Analyst ForecastBIIBBiogen4.9586 of 5 stars$125.59-0.4%$188.48+50.1%-41.0%$18.47B$9.68B12.407,605Positive News Related Companies and Tools Related Companies FBIO Competitors CRIS Competitors BOLT Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
